Nicola J Curtin

17PUBLICATIONS
15CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Nov 12, 2024
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications.

Yvette Drew, Frank T Zenke, Nicola J Curtin

|Jul 04, 2024
ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors.

Hannah L Smith, Elaine Willmore, Lisa Prendergast

|Jan 06, 2023
Targeting the DNA damage response for cancer therapy.

Nicola J Curtin

|Nov 26, 2022
Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling.

Hannah L Smith, Elaine Willmore, Asima Mukhopadhyay

|Sep 09, 2022
Determining the Potential of DNA Damage Response (DDR) Inhibitors in Cervical Cancer Therapy.

Santu Saha, Stuart Rundle, Ioannis C Kotsopoulos

|Aug 12, 2022
The Role of ATR Inhibitors in Ovarian Cancer: Investigating Predictive Biomarkers of Response.

Alice Bradbury, Frank T Zenke, Nicola J Curtin

Pageof 3

Frequent Collaborators

3 joint publications

Yvette Drew

2 joint publications

Hannah L Smith

1 joint publications

Péter Bai

1 joint publications

Stuart Rundle